Download PDF
Semin Respir Crit Care Med 2008; 29(1): 047-055
DOI: 10.1055/s-2008-1047562
© Thieme Medical Publishers

Massive Pulmonary Embolism: What Level of Aggression?

Stavros V. Konstantinides1
  • 1Department of Cardiology and Pulmonary Medicine, Georg August University of Goettingen, Goettingen, Germany
Further Information

Publication History

Publication Date:
26 March 2008 (online)

    Permissions and Reprints

ABSTRACT

Massive pulmonary embolism (PE) with hemodynamic instability (e.g., hypotension and cardiac shock) is associated with a poor prognosis and high mortality rates (> 50%). Accordingly patients with massive PE should be treated aggressively with thrombolytic agents (or surgical or interventional procedures). Streptokinase, urokinase, and recombinant tissue plasminogen activator (rtPA) have been used, with generally similar results. Among patients with submassive PE [i.e., subclinical right ventricular (RV) dysfunction and normal blood pressure], the role of thrombolytic therapy is controversial. Thrombolytic therapy is generally not indicated in normotensive patients without RV dysfunction. In this context, some experts recommend prompt administration of thrombolytic agents to prevent cardiogenic shock but data affirming benefit over heparin alone are lacking. Thrombolytic therapy is generally not indicated in normotensive patients without RV dysfunction. The role of echocardiography, computed tomographic (CT) scans, and cardiac biomarkers (e.g., troponins, brain natriuretic peptide, etc.) to identify patients who might benefit from aggressive thrombolytic therapy remains controversial. This article reviews indications for thrombolysis in massive PE, with an emphasis on recent data derived from normotensive patients. Further, we propose a diagnostic and therapeutic algorithm for treating acute PE. Additional studies are required to determine the benefit and safety of thrombolytic therapy for PE.

KEYWORDS

Thrombolysis - massive pulmonary embolism - right ventricular dysfunction - urokinase - streptokinase - recombinant tissue thromboplastin activator

REFERENCES

  • 1 McIntyre K M, Sasahara A A. Determinants of right ventricular function and hemodynamics after pulmonary embolism.  Chest. 1974;  65 534-543
    CrossrefPubMedGoogle Scholar
  • 2 McIntyre K M, Sasahara A A. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease.  Am J Cardiol. 1971;  28 288-294
    CrossrefPubMedGoogle Scholar
  • 3 Lualdi J C, Goldhaber S Z. Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications.  Am Heart J. 1995;  130 1276-1282
    CrossrefPubMedGoogle Scholar
  • 4 Kasper W, Konstantinides S, Geibel A et al.. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.  , [see comments] J Am Coll Cardiol. 1997;  30 1165-1171
    CrossrefPubMedGoogle Scholar
  • 5 European Society of Cardiology TFoPE . Guidelines on diagnosis and management of acute pulmonary embolism.  Eur Heart J. 2000;  21 1301-1336
    CrossrefPubMedGoogle Scholar
  • 6 British Thoracic Society . Guidelines for the management of suspected acute pulmonary embolism.  Thorax. 2003;  58 470-483
    CrossrefPubMedGoogle Scholar
  • 7 Kucher N, Goldhaber S Z. Management of massive pulmonary embolism.  Circulation. 2005;  112 e28-e32
    CrossrefPubMedGoogle Scholar
  • 8 Dalen J E. Thrombolysis in submassive pulmonary embolism? No.  J Thromb Haemost. 2003;  1 1130-1132
    CrossrefPubMedGoogle Scholar
  • 9 Konstantinides S. Thrombolysis in submassive pulmonary embolism? Yes.  J Thromb Haemost. 2003;  1 1127-1129
    CrossrefPubMedGoogle Scholar
  • 10 Goldhaber S Z. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro.  Arch Intern Med. 2005;  165 2197-2199
    CrossrefPubMedGoogle Scholar
  • 11 Thabut G, Logeart D. Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: con.  Arch Intern Med. 2005;  165 2200-2203
    CrossrefPubMedGoogle Scholar
  • 12 The urokinase pulmonary embolism trial: a national cooperative study.  Circulation. 1973;  47 II1-108
    PubMedGoogle Scholar
  • 13 Tibbutt D A, Davies J A, Anderson J A et al.. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism.  BMJ. 1974;  1 343-347
    CrossrefPubMedGoogle Scholar
  • 14 Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism.  Acta Med Scand. 1978;  203 465-470
    PubMedGoogle Scholar
  • 15 Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial.  Respiration. 1988;  54 162-173
    CrossrefPubMedGoogle Scholar
  • 16 Levine M, Hirsh J, Weitz J et al.. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.  Chest. 1990;  98 1473-1479
    CrossrefPubMedGoogle Scholar
  • 17 The PIOPED Investigators . Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study.  Chest. 1990;  97 528-533
    PubMedGoogle Scholar
  • 18 Dalla-Volta S, Palla A, Santolicandro A et al.. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: plasminogen activator Italian multicenter study 2.  J Am Coll Cardiol. 1992;  20 520-526
    CrossrefPubMedGoogle Scholar
  • 19 Goldhaber S Z, Haire W D, Feldstein M L et al.. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.  Lancet. 1993;  341 507-511
    CrossrefPubMedGoogle Scholar
  • 20 Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism.  Am J Cardiol. 1998;  82 966-970
    CrossrefPubMedGoogle Scholar
  • 21 Urokinase-streptokinase embolism trial: phase 2 results: a cooperative study.  JAMA. 1974;  229 1606-1613
    CrossrefPubMedGoogle Scholar
  • 22 Meyer G, Sors H, Charbonnier B et al.. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.  , [see comments] J Am Coll Cardiol. 1992;  19 239-245
    PubMedGoogle Scholar
  • 23 Goldhaber S Z, Kessler C M, Heit J et al.. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.  Lancet. 1988;  2 293-298
    PubMedGoogle Scholar
  • 24 Meneveau N, Schiele F, Metz D et al.. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.  J Am Coll Cardiol. 1998;  31 1057-1063
    CrossrefPubMedGoogle Scholar
  • 25 Meneveau N, Schiele F, Vuillemenot A et al.. Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.  Eur Heart J. 1997;  18 1141-1148
    PubMedGoogle Scholar
  • 26 Goldhaber S Z, Agnelli G, Levine M N. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.  Chest. 1994;  106 718-724
    CrossrefPubMedGoogle Scholar
  • 27 Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial.  Chest. 1994;  106 712-717
    CrossrefPubMedGoogle Scholar
  • 28 Verstraete M, Miller G A, Bounameaux H et al.. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.  Circulation. 1988;  77 353-360
    CrossrefPubMedGoogle Scholar
  • 29 Tebbe U, Graf A, Kamke W et al.. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.  Am Heart J. 1999;  138 39-44
    CrossrefPubMedGoogle Scholar
  • 30 Kline J A, Hernandez-Nino J, Jones A E. Tenecteplase to treat pulmonary embolism in the emergency department.  J Thromb Thrombolysis. 2007;  23 101-105
    CrossrefPubMedGoogle Scholar
  • 31 Meneveau N, Seronde M F, Blonde M C et al.. Management of unsuccessful thrombolysis in acute massive pulmonary embolism.  Chest. 2006;  129 1043-1050
    CrossrefPubMedGoogle Scholar
  • 32 Daniels L B, Parker J A, Patel S R, Grodstein F, Goldhaber S Z. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.  Am J Cardiol. 1997;  80 184-188
    CrossrefPubMedGoogle Scholar
  • 33 Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.  N Engl J Med. 2002;  347 1143-1150
    CrossrefPubMedGoogle Scholar
  • 34 Kanter D S, Mikkola K M, Patel S R, Parker J A, Goldhaber S Z. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors.  Chest. 1997;  111 1241-1245
    CrossrefPubMedGoogle Scholar
  • 35 Goldhaber S Z, Kessler C M, Heit J A et al.. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.  J Am Coll Cardiol. 1992;  20 24-30
    PubMedGoogle Scholar
  • 36 Stein P D, Hull R D, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism: consideration of noninvasive management.  , [see comments] Ann Intern Med. 1994;  121 313-317
    PubMedGoogle Scholar
  • 37 Wan S, Quinlan D J, Agnelli G, Eikelboom J W. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials.  Circulation. 2004;  110 744-749
    CrossrefPubMedGoogle Scholar
  • 38 Kasper W, Konstantinides S, Geibel A et al.. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.  J Am Coll Cardiol. 1997;  30 1165-1171
    CrossrefPubMedGoogle Scholar
  • 39 Kucher N, Rossi E, De Rosa M, Goldhaber S Z. Massive pulmonary embolism.  Circulation. 2006;  113 577-582
    CrossrefPubMedGoogle Scholar
  • 40 Stein P D, Henry J W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.  Chest. 1995;  108 978-981
    CrossrefPubMedGoogle Scholar
  • 41 Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes G et al.. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.  J Thromb Thrombolysis. 1995;  2 227-229
    CrossrefPubMedGoogle Scholar
  • 42 Rose P S, Punjabi N M, Pearse D B. Treatment of right heart thromboemboli.  Chest. 2002;  121 806-814
    CrossrefPubMedGoogle Scholar
  • 43 Chartier L, Bera J, Delomez M et al.. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients.  Circulation. 1999;  99 2779-2783
    CrossrefPubMedGoogle Scholar
  • 44 Grifoni S, Olivotto I, Cecchini P et al.. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction.  Circulation. 2000;  101 2817-2822
    CrossrefPubMedGoogle Scholar
  • 45 Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism.  Heart. 1997;  77 346-349
    PubMedGoogle Scholar
  • 46 Vieillard-Baron A, Page B, Augarde R et al.. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate.  Intensive Care Med. 2001;  27 1481-1486
    CrossrefPubMedGoogle Scholar
  • 47 Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis.  , [see comments] Circulation. 1999;  99 1325-1330
    CrossrefPubMedGoogle Scholar
  • 48 Kucher N, Rossi E, De Rosa M, Goldhaber S Z. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher.  Arch Intern Med. 2005;  165 1777-1781
    CrossrefPubMedGoogle Scholar
  • 49 ten Wolde M, Sohne M, Quak E, Mac Gillavry M R, Buller H R. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism.  Arch Intern Med. 2004;  164 1685-1689
    CrossrefPubMedGoogle Scholar
  • 50 Kasper W, Geibel A, Tiede N et al.. Distinguishing between acute and subacute massive pulmonary embolism by conventional and Doppler echocardiography.  Br Heart J. 1993;  70 352-356
    PubMedGoogle Scholar
  • 51 Schoepf U J, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber S Z. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism.  Circulation. 2004;  110 3276-3280
    CrossrefPubMedGoogle Scholar
  • 52 van der Meer R W, Pattynama P M, van Strijen M J et al.. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism.  Radiology. 2005;  235 798-803
    CrossrefPubMedGoogle Scholar
  • 53 Perrier A, Roy P M, Sanchez O et al.. Multidetector-row computed tomography in suspected pulmonary embolism.  N Engl J Med. 2005;  352 1760-1768
    CrossrefPubMedGoogle Scholar
  • 54 Janata K, Holzer M, Laggner A N, Mullner M. Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study.  BMJ. 2003;  326 312-313
    CrossrefPubMedGoogle Scholar
  • 55 Pruszczyk P, Bochowicz A, Torbicki A et al.. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism.  Chest. 2003;  123 1947-1952
    CrossrefPubMedGoogle Scholar
  • 56 Konstantinides S, Geibel A, Olschewski M et al.. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism.  Circulation. 2002;  106 1263-1268
    CrossrefPubMedGoogle Scholar
  • 57 Giannitsis E, Muller-Bardorff M, Kurowski V et al.. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism.  Circulation. 2000;  102 211-217
    CrossrefPubMedGoogle Scholar
  • 58 Kucher N, Goldhaber S Z. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism.  Circulation. 2003;  108 2191-2194
    CrossrefPubMedGoogle Scholar
  • 59 Bova C, Crocco F, Ricchio R, Serafini O, Greco F, Noto A. Importance of troponin T for the risk stratification of normotensive patients with pulmonary embolism: a prospective, cohort study with a three-month follow-up.  Haematologica. 2005;  90 423-424
    PubMedGoogle Scholar
  • 60 La Vecchia L, Ottani F, Favero L et al.. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism.  Heart. 2004;  90 633-637
    CrossrefPubMedGoogle Scholar
  • 61 Yalamanchili K, Sukhija R, Aronow W S, Sinha N, Fleisher A G, Lehrman S G. Prevalence of increased cardiac troponin I levels in patients with and without acute pulmonary embolism and relation of increased cardiac troponin I levels with in-hospital mortality in patients with acute pulmonary embolism.  Am J Cardiol. 2004;  93 263-264
    CrossrefPubMedGoogle Scholar
  • 62 Binder L, Pieske B, Olschewski M et al.. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism.  Circulation. 2005;  112 1573-1579
    CrossrefPubMedGoogle Scholar
  • 63 Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess O M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism.  Circulation. 2003;  107 1576-1578
    CrossrefPubMedGoogle Scholar
  • 64 Kucher N, Printzen G, Goldhaber S Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism.  Circulation. 2003;  107 2545-2547
    CrossrefPubMedGoogle Scholar
  • 65 Pruszczyk P, Kostrubiec M, Bochowicz A et al.. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism.  Eur Respir J. 2003;  22 649-653
    CrossrefPubMedGoogle Scholar
  • 66 ten Wolde M, Tulevski I I, Mulder J W et al.. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism.  Circulation. 2003;  107 2082-2084
    CrossrefPubMedGoogle Scholar
  • 67 Krüger S, Graf J, Merx M W et al.. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism.  Am Heart J. 2004;  147 60-65
    CrossrefPubMedGoogle Scholar
  • 68 Giannitsis E, Katus H A. Risk stratification in pulmonary embolism based on biomarkers and echocardiography.  Circulation. 2005;  112 1520-1521
    CrossrefPubMedGoogle Scholar
  • 69 Storch J, Thumser A E. The fatty acid transport function of fatty acid-binding proteins.  Biochim Biophys Acta. 2000;  1486 28-44
    PubMedGoogle Scholar
  • 70 Alhadi H A, Fox K A. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein.  QJM. 2004;  97 187-198
    CrossrefPubMedGoogle Scholar
  • 71 Pelsers M M, Hermens W T, Glatz J F. Fatty acid-binding proteins as plasma markers of tissue injury.  Clin Chim Acta. 2005;  352 15-35
    CrossrefPubMedGoogle Scholar
  • 72 Puls M, Dellas C, Lankeit M et al.. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism.  Eur Heart J. 2007;  28 224-229
    PubMedGoogle Scholar
  • 73 Kaczynska A, Pelsers M M, Bochowicz A, Kostrubiec M, Glatz J F, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism.  Clin Chim Acta. 2006;  371 117-123
    CrossrefPubMedGoogle Scholar
  • 74 Scridon T, Scridon C, Skali H, Alvarez A, Goldhaber S Z, Solomon S D. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism.  Am J Cardiol. 2005;  96 303-305
    CrossrefPubMedGoogle Scholar

Stavros V KonstantinidesM.D. 

Department of Cardiology and Pulmonary Medicine, Georg August University of Goettingen

Robert Koch Str. 40, D-37075, Goettingen, Germany

Email: skonstan@med.uni-goettingen.de

      >